Wang Q, et al. - In this randomised controlled trial, researchers ascertained if the use of routine, non-selective stenting in angioplasty could improve patency and treatment effectiveness with adequate safety in Budd-Chiari syndrome. Eligible participants were patients (aged 18 to 75 years) with Budd-Chiari syndrome with a membranous obstruction or short-length stenosis (≤4 cm) and a Child-Pugh score of less than 13. Data reported that the hazard ratio for restenosis was 0·04 in favour of routine stenting, with an absolute risk reduction of 35·6%. The authors concluded that routine angioplasty stenting in patients with Budd-Chiari syndrome with short-length stenosis is superior to angioplasty alone for the prevention of restenosis and is secure to use as part of first-line invasive therapy. In similar settings and other regions where different features of Budd-Chiari syndrome are more prevalent, further validation is required. There was no stent fracture or migration.